AstraZeneca (AZN) Reels from China Investigation and Investor Suit–Hagens Berman

SAN FRANCISCO, Jan. 15, 2025 (GLOBE NEWSWIRE) -- AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health insurance fraud has cast a shadow over the company’s prospects in a critical market, triggering a securities class action lawsuit in the United St ...